BerGenBio ASA
BGBIO.OL
Get informed when a big investor buys or sells
+ FollowMarket Cap$45.73M
Close$
Share Statistics
| Market cap | $45.73 Million |
|---|---|
| Enterprise Value | $-59,006,074.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.95 |
| Beta | 1.19 |
| Outstanding Shares | 39,087,116 |
Return
| Return on Equity | -345.68% |
|---|---|
| Return on Assets | -217.36% |
| Return on Invested Capital | -327.23% |
Valuation & Multiples
| P/E Ratio | -0.84 |
|---|---|
| PEG | -3.26 |
| Price to Sales | - |
| Price to Book Ratio | 0.59 |
| Enterprise Value to Revenue | 376.86 |
| Enterprise Value to EBIT | -35.58 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Oncoinvent ASA
44 employees
CEO: Oystein Soug Oncoinvent ASA is a biopharmaceutical firm dedicated to creating novel therapies for cancer. The company concentrates its efforts on building a diverse range of AXL kinase inhibitors. Its flagship product, bemcentinib, stands out as a hi...